Eylea Market Size was valued at USD 7.5 Billion in 2022. The Eylea market industry is projected to grow from USD 7.82 Billion in 2023 to USD 10.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.20% during the forecast period (2023 - 2032). Superior performance in treating ocular illnesses and rising rates of retinal disorders are the key market drivers boosting the expansion of the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Market CAGR for Eylea is being driven by the rising incidence of eye conditions. Aflibercept, a synthetic fusion protein with a molecular weight of 97 kDa, is used in the medication Eylea to treat retinal disorders. Eylea is approved by the US Food and Drug Administration (US FDA) to treat age-related macular degeneration, myopic choroidal neovascularization, diabetic retinopathy, and retinal vein occlusion. Eylea is an inhibitor of Vascular Endothelial Growth Factor (VEGF), a naturally occurring protein in the body that primarily aids in the development of new blood vessels.
Additionally, the market for eylea is expanding quickly primarily because eye illnesses are becoming more common, particularly in the elderly population. While wet AMD is less common, there are notable occurrences of dry AMD in the elderly population. Due of the high percentage of people worldwide who suffer from diabetes, the eylea market is expanding rapidly. Diabetic retinopathy is a complex retinal disorder mostly caused by elevated blood sugar levels, and diabetes is one of the main causes of it. An increasing number of working women and stressful work environments have led to a greater emphasis on ready-to-eat meals, which has increased the incidence of diabetes and driven market expansion.
The development, distribution, and marketing of Eylea are facilitated by partnerships among pharmaceutical corporations, healthcare providers, and research organizations. The development of evidence proving the safety and efficacy of Eylea is aided by ongoing clinical trials and research funding in the area of retinal disorders, which further propels the product's market expansion. Promoting knowledge about retinal illnesses and the range of treatment choices, including Eylea, is largely dependent on educational activities and awareness campaigns aimed at patients as well as healthcare professionals.
For instance, the United Nations estimates that there were about 703 million people over 65 worldwide in 2019. The proportion of the population at risk of developing age-related macular degeneration rises with the number of elderly people. Thus, result in driving the Eylea market revenue.
The Eylea market segmentation, based on product includes Prefilled Syringe Package, and Vial Package. The Prefilled Syringe Package segment dominated the market. One benefit of prefilled syringes over conventional vial packaging is their simplicity of use. With evolving regulations and increasingly complex medication administration methods, prefilled syringe demand is steadily rising. Given that syringes have advanced significantly in recent years and that research is continuously being done to create new goods, there is expected to be a large increase in demand.
The Eylea market segmentation, based on Application, includes Hospitals, Retail Pharmacy, and Others. The Hospitals category generated the most income. The rising frequency of patients with diabetic retinopathy, wet age-related macular degeneration (AMD), and other retinal conditions that need medical professionals' attention for appropriate treatment is the primary cause of the hospital segment's expansion. Hospitals are facilities under health supervision that offer medical equipment, auxiliary healthcare workers, and specialist health sciences to treat patients.
Figure1:Eylea Market, by Application, 2022 & 2032(USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Eylea market area will dominate this market. Effective treatment alternatives, like Eylea, are in high demand because to the high frequency of retinal illnesses in the North American population, including wet AMD, DME, and RVO.
Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.
Figure2:Eylea Market Share By Region 2022 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe Eylea market has the second-largest portion of the market. Growing Eylea's indications and regulatory approvals for treating a range of retinal diseases fuel the product's expansion. Further, the German Eylea market had the biggest market share, and the UK Eylea market was the fastest growing market in the European region
The Asia-Pacific Eylea Market is anticipated to expand between 2023 and 2032 at the quickest CAGR. A increased incidence of diabetic macular edema is a result of the Asia-Pacific region's growing diabetes prevalence. Moreover, China’s Eylea market had the biggest market share, and the Indian Eylea market was the fastest growing market in the Asia-Pacific region.
Eylea Key Market Players& Competitive Insights
Leading market players are putting a lot of money on R&D to expand their product lines, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. to grow and endure in an increasingly cutthroat and dynamic market, Eylea industry must provide reasonably priced goods.
Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the Eylea industry to help customers and expand the market segment. In recent years, the Eylea industry has provided some of the biggest benefits to medicine. Major players in the Eylea market, including Amgen Inc., Roche Holding AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, and others, are attempting to increase market demand by investing in research and development operations.
With its headquarters located in Westchester County, New York, Regeneron Pharmaceuticals, Inc. is an American biotechnology business. 1988 saw the founding of the business.In [2] The company got its start researching neurotrophic factors and their ability to regenerate tissue. This led to a branch out into the study of tyrosine kinase and cytokine receptors, which resulted in the development of their first product, a VEGF-trap. In April 2022, The company declared that it would pay approximately $250 million to purchase Checkmate Pharmaceuticals, increasing the quantity of immuno-oncology medications it offers.
One of the biggest pharmaceutical and biomedical corporations in the world is Bayer AG, a multinational pharmaceutical and biotechnology firm based in Germany. Bayer, who has its headquarters in Leverkusen, is a company that deals in pharmaceuticals, consumer healthcare goods, seeds, agricultural chemicals, and biotechnology products. The company is included in the stock market index known as EURO STOXX 50. In June 2021, the business declared that it has acquired PSMA Therapeutics Inc. and Noria Therapeutics Inc., acquiring the rights to several actinium-225-based cancer-based experimental drugs.
Key Companies in the Eylea market include
Eylea Industry Developments
February 2023:Retinopathy of prematurity (ROP) in preterm neonates can now be treated with EYLEA (aflibercept) Injection, according to Regeneron Pharmaceuticals, Inc.
August 2020:Bayer announced the acquisition of KaNDy Therapeutics Ltd., for $425 million, which would assist grow its business in the female healthcare market.
March 2023:Seagen was agreed to be acquired by Pfizer for an estimated $43 billion in total enterprise value. The European Commission is investigating antitrust in this regard, which is required in order for the merger to be approved.
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 7.5 Billion |
| Market Size 2023 | USD 7.8 Billion |
| Market Size 2032 | USD 10.9 Billion |
| Compound Annual Growth Rate (CAGR) | 4.20% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Application, and Region |
| Geographies Covered | North America, Europe, Asia-Pacific, and the Rest of the World |
| Countries Covered | The US, German, France, UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil |
| Key Companies Profiled | Â Amgen Inc., Roche Holding AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company |
| Key Market Opportunities | Growing Retinal Disease Incidence will propel market expansion |
| Key Market Dynamics | Superior Visual Outcomes and Extended Dosing Intervals will propel market expansion. |
Frequently Asked Questions (FAQ) :
In 2022, the size of the worldwide eylea market was estimated to be USD 7.5 billion.
From 2023 to 2032, the market is expected to expand at a compound annual growth rate (CAGR) of 4.20%.
North America held the most market share worldwide.
Amgen Inc., Roche Holding AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company are the major participants in the market.
The market was dominated in 2022 by the Prefilled Syringe Package category.
The biggest market share worldwide belonged to hospitals.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
